Inclusion Body Myositis - Pipeline Insight, 2025

The “Inclusion Body Myositis- Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Inclusion Body Myositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Inclusion Body Myositis: Understanding

Inclusion Body Myositis: Overview

Inclusion Body Myositis (IBM) is a rare, progressive muscle disorder characterized by muscle weakness and wasting, primarily affecting the thighs, forearms, and swallowing muscles. It is the most common inflammatory myopathy in older adults, typically developing after age 50. The exact cause is unclear, but it involves both inflammatory and degenerative processes. IBM is challenging to treat, with limited response to immunosuppressive therapies. Inclusion body myositis (IBM) is the most prevalent myopathy in adults older than age fifty, with over 50,000 patients estimated in the United States and Europe. The disease is characterized by progressive weakness and atrophy of muscles of the arms and the legs, as well as muscles involved in swallowing. IBM is chronically progressive and results in severe disability and premature death. There are currently no available therapeutic options for IBM. Non-specific immunosuppressants or corticosteroids have not demonstrated efficacy in IBM and thus, are not widely used.

The common symptoms includes gradual weakening, particularly in the quadriceps and forearm flexors, leading to difficulty standing, walking, or gripping objects. Visible muscle atrophy in the affected areas, worsening over time. Trouble swallowing, which may increase the risk of choking or aspiration pneumonia. Muscle weakness is often uneven, affecting one side of the body more than the other.Frequent falls due to weakened leg muscles and impaired balance. The pathophysiology of Inclusion Body Myositis (IBM) involves a combination of inflammatory and degenerative processes. Chronic inflammation, driven by T-cell infiltration and cytokine release, damages muscle tissue. Simultaneously, protein misfolding and the accumulation of abnormal protein aggregates, including beta-amyloid and tau, contribute to muscle degeneration. Mitochondrial dysfunction and impaired autophagy further exacerbate muscle damage. These dual mechanisms lead to progressive muscle weakness and atrophy.

The diagnosis of Inclusion Body Myositis (IBM) involves a combination of clinical evaluation, laboratory tests, and muscle biopsy. Blood tests may reveal mildly elevated creatine kinase (CK) levels. Electromyography (EMG) helps detect abnormal electrical activity in affected muscles. MRI can highlight muscle inflammation and atrophy patterns. A definitive diagnosis is made through muscle biopsy, which reveals characteristic features such as inflammatory cell infiltration, vacuoles, and abnormal protein inclusions (e.g., beta-amyloid deposits). Treatment for Inclusion Body Myositis (IBM) focuses on symptom management, as there is no cure. Physical therapy helps maintain muscle strength and mobility, while assistive devices (like canes or braces) support daily activities. Immunosuppressive therapies, such as corticosteroids or intravenous immunoglobulin (IVIG), typically show limited effectiveness. Dysphagia may require dietary modifications or swallowing therapy. Ongoing research is exploring potential therapies, including targeted immunomodulators and regenerative approaches.

"Inclusion Body Myositis- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inclusion Body Myositis pipeline landscape is provided which includes the disease overview and Inclusion Body Myositis treatment guidelines. The assessment part of the report embraces, in depth Inclusion Body Myositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inclusion Body Myositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Inclusion Body Myositis R&D. The therapies under development are focused on novel approaches to treat/improve Inclusion Body Myositis.

Inclusion Body Myositis Emerging Drugs Chapters

This segment of the Inclusion Body Myositis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Inclusion Body Myositis Emerging Drugs

• ABC008: Abcuro, Inc.

Ulviprubart (ABC008) is a first-in-class anti-KLRG1 antibody product candidate capable of selectively depleting highly cytotoxic T cells, while sparing naïve, regulatory and central memory T cells. Ulviprubart (ABC008) is designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM), T cell large granular lymphocytic leukemia (T-LGLL), and mature T cell malignancies. Currently, the drug is in the Phase II/ III stage of its development for the treatment of Inclusion Body Myositis.

Inclusion Body Myositis: Therapeutic Assessment

This segment of the report provides insights about the different Inclusion Body Myositis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Inclusion Body Myositis

There are approx. 2+ key companies which are developing the therapies for Inclusion Body Myositis. The companies which have their Inclusion Body Myositis drug candidates in the most advanced stage, i.e. Phase II/III include, Abcuro, Inc.

Phases

The report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Inclusion Body Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Inclusion Body Myositis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inclusion Body Myositis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inclusion Body Myositis drugs.

Inclusion Body Myositis Report Insights

• Inclusion Body Myositis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Inclusion Body Myositis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Inclusion Body Myositis drugs?
• How many Inclusion Body Myositis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inclusion Body Myositis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Inclusion Body Myositis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Inclusion Body Myositis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Abcuro, Inc.
• Regeneron Pharmaceuticals
• Vandria

Key Products

• ABC008
• Pozelimab+Cemdisiran
• VNA-052

This product will be delivered within 2 business days.